Aspira Pathlab

{
  "main_header": {
    "sid": 1002885,
    "name": "Aspira Pathlab",
    "stock_name": "Aspira Pathlab",
    "full_name": "Aspira Pathlab & Diagnostics Ltd",
    "name_url": "stocks-analysis/aspira-pathlab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "63.00",
    "chg": -4,
    "chgp": "-5.97%",
    "dir": -1,
    "prev_price": "67.00",
    "mcapval": "64.85 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540788,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE500C01017",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": 795,
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aspira-pathlab-1002885-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Aspira Pathlab & Diagnostics Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-aspira-pathlab-diagnostics-ltd-fallingrising-3790770",
        "imagepath": "",
        "date": "2026-01-14 00:55:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Despite the stock's positive performance on 13-Jan, its recent returns over various timeframes reveal a mixed picture. Over the past week, Aspira Pathlab's shares declined by 0.77%, though this was less severe than the Sensex's 1.69% drop. The one-month return shows a sharper fall of 4.63%, compared to the Sensex's 1.92% decline. Year-to-date, the stock has marginally decreased by 1.04%, slightly outperforming the Sensex's 1.87% fall. However, over the last year, Aspira Pathlab has underperformed significantly, with an 18.08% loss against the Sensex's 9.56% gain. On a longer horizon, the stock has delivered robust returns, rising 55.56% over three years, outpacing the Sensex's 38.78% gain.</p>\n<p><strong>Technical Indicators Driving..."
      },
      {
        "title": "Aspira Pathlab &amp; Diagnostics Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-hold-3784547",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AspiraPathlabDi_mojoScore_3784547.png",
        "date": "2026-01-07 10:10:08",
        "description": "Aspira Pathlab &amp; Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-ltd-is-rated-hold-3772016",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3772016.png",
        "date": "2025-12-27 10:10:04",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 December 2025, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Financial and Technical Developments",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-upgraded-to-hold-on-improved-technicals-and-strong-financials-3759706",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3759706.png",
        "date": "2025-12-16 08:48:05",
        "description": "Aspira Pathlab & Diagnostics has experienced a notable revision in market assessment following a comprehensive review of its quality, valuation, financial trends, and technical indicators. This shift reflects evolving dynamics in the healthcare services sector and the company’s recent performance metrics."
      },
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Revisions Reflect Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3753106",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3753106.png",
        "date": "2025-12-09 09:04:05",
        "description": "Aspira Pathlab & Diagnostics has recently undergone a revision in its market evaluation, reflecting a nuanced shift in analytical perspectives across key parameters including quality, valuation, financial trends, and technical indicators. This article examines the factors influencing these changes and their implications for investors in the healthcare services sector."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Hits Upper Circuit Amidst Unprecedented Buying Interest",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-hits-upper-circuit-amidst-unprecedented-buying-frenzy-3741016",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_only_buyers_3741016.png",
        "date": "2025-12-02 09:36:27",
        "description": "Aspira Pathlab & Diagnostics has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. The stock’s performance today stands out sharply against the broader market, signalling robust investor enthusiasm and the potential for a sustained multi-day circuit scenario."
      },
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-upgraded-to-hold-on-improved-technicals-and-strong-financials-3740762",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3740762.png",
        "date": "2025-12-02 08:59:32",
        "description": "Aspira Pathlab & Diagnostics has experienced a revision in its market assessment, reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent analytical perspective shifts for the healthcare services company, highlighting its financial performance, market behaviour, and technical signals."
      },
      {
        "title": "How has been the historical performance of Aspira Pathlab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-aspira-pathlab-3739372",
        "imagepath": "",
        "date": "2025-12-01 23:33:21",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue Growth and Profitability Improvement</strong></p>\n<p>In the fiscal year ending March 2025, Aspira Pathlab reported consolidated net sales of ₹22.00 crore, marking a significant increase from ₹13.20 crore in the previous year. This growth of approximately 66.7% underscores the company’s expanding market presence and operational scale. Despite no other operating income reported in either year, the total operating income mirrored net sales, reflecting a focused revenue stream.</p>\n<p>Cost management remained a critical factor in the company’s improved profitability. Raw material costs rose moderately from ₹2.62 crore to ₹3.70 crore, while employee expenses increased from ₹6.20 crore to ₹7.33 crore, consistent with the company’s growth trajectory. Selling and distribution expenses remain..."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Sees Unprecedented Buying Interest, Edging Towards Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-hits-upper-circuit-amid-unprecedented-buying-interest-3738838",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_only_buyers_3738838.png",
        "date": "2025-12-01 14:50:36",
        "description": "Aspira Pathlab & Diagnostics Ltd has captured the market’s attention with extraordinary buying momentum, registering a 4.98% gain today while the broader Sensex slipped marginally by 0.07%. The stock’s unique position of having only buy orders in the queue signals a potential multi-day upper circuit scenario, underscoring robust investor demand in the healthcare services sector."
      }
    ],
    "total": 6125,
    "sid": "1002885",
    "stock_news_url": "https://www.marketsmojo.com/news/aspira-pathlab-diagnostics-1002885"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "07-Jan-2026",
      "details": "Newspaper Publication-Postal Ballot",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Compliance Certificate under reg 74(5) of SEBI (DP) Regulations 2018 for the quarter ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
      "datetime": "06-Jan-2026",
      "details": "Intimation of Postal Ballot Notice for appointment of Mrs. Kiran Awasthi (DIN:09066721) as an Independent Director for the first term of 5 consecutive years",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

2026-01-14 00:55:20

Recent Price Performance and Market Context

Despite the stock's positive performance on 13-Jan, its recent returns over various timeframes reveal a mixed picture. Over the past week, Aspira Pathlab's shares declined by 0.77%, though this was less severe than the Sensex's 1.69% drop. The one-month return shows a sharper fall of 4.63%, compared to the Sensex's 1.92% decline. Year-to-date, the stock has marginally decreased by 1.04%, slightly outperforming the Sensex's 1.87% fall. However, over the last year, Aspira Pathlab has underperformed significantly, with an 18.08% loss against the Sensex's 9.56% gain. On a longer horizon, the stock has delivered robust returns, rising 55.56% over three years, outpacing the Sensex's 38.78% gain.

Technical Indicators Driving...

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Hold

2026-01-07 10:10:08

Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Hold

2025-12-27 10:10:04

Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Financial and Technical Developments

2025-12-16 08:48:05

Aspira Pathlab & Diagnostics has experienced a notable revision in market assessment following a comprehensive review of its quality, valuation, financial trends, and technical indicators. This shift reflects evolving dynamics in the healthcare services sector and the company’s recent performance metrics.

Read full news article

Aspira Pathlab & Diagnostics: Analytical Revisions Reflect Mixed Market Signals

2025-12-09 09:04:05

Aspira Pathlab & Diagnostics has recently undergone a revision in its market evaluation, reflecting a nuanced shift in analytical perspectives across key parameters including quality, valuation, financial trends, and technical indicators. This article examines the factors influencing these changes and their implications for investors in the healthcare services sector.

Read full news article

Aspira Pathlab & Diagnostics Hits Upper Circuit Amidst Unprecedented Buying Interest

2025-12-02 09:36:27

Aspira Pathlab & Diagnostics has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. The stock’s performance today stands out sharply against the broader market, signalling robust investor enthusiasm and the potential for a sustained multi-day circuit scenario.

Read full news article

Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Mixed Market Signals

2025-12-02 08:59:32

Aspira Pathlab & Diagnostics has experienced a revision in its market assessment, reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent analytical perspective shifts for the healthcare services company, highlighting its financial performance, market behaviour, and technical signals.

Read full news article

How has been the historical performance of Aspira Pathlab?

2025-12-01 23:33:21

Revenue Growth and Profitability Improvement

In the fiscal year ending March 2025, Aspira Pathlab reported consolidated net sales of ₹22.00 crore, marking a significant increase from ₹13.20 crore in the previous year. This growth of approximately 66.7% underscores the company’s expanding market presence and operational scale. Despite no other operating income reported in either year, the total operating income mirrored net sales, reflecting a focused revenue stream.

Cost management remained a critical factor in the company’s improved profitability. Raw material costs rose moderately from ₹2.62 crore to ₹3.70 crore, while employee expenses increased from ₹6.20 crore to ₹7.33 crore, consistent with the company’s growth trajectory. Selling and distribution expenses remain...

Read full news article

Aspira Pathlab & Diagnostics Sees Unprecedented Buying Interest, Edging Towards Multi-Day Upper Circuit

2025-12-01 14:50:36

Aspira Pathlab & Diagnostics Ltd has captured the market’s attention with extraordinary buying momentum, registering a 4.98% gain today while the broader Sensex slipped marginally by 0.07%. The stock’s unique position of having only buy orders in the queue signals a potential multi-day upper circuit scenario, underscoring robust investor demand in the healthcare services sector.

Read full news article

View All News